Warburg Pincus acquires domestic formulations company Integrace, for an undisclosed sum

Warburg Pincus has acquired Integrace Private Ltd, a domestic formulations company focused on orthopaedics and gynecology, for an undisclosed sum.

Integrace has more than 20 brands in its portfolio and has undertaken acquisitions of brands and business, from Zydus and Glenmark, respectively in the last six years. As part of the latest transaction, existing shareholders True North and Temasek will fully exit their investment in the company, a note on the development said.

Rehan Khan, former Managing Director at MSD and Abbott India Limited, will join Integrace as Chief Executive Officer to lead the company, in partnership with Warburg Pincus, a note on the development said.

Himanshu Nema, Managing Director, Warburg Pincus, said in a statement that Integrace has a differentiated portfolio in orthopaedics and gynecology. “This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India,” he added.

Rehan Khan, Chief Executive Officer, Integrace, pointed out that India’s pharmaceutical market was large and attractive with predictable growth over the long-term, particularly in women’s health and orthopedic therapies.

Warburg Pincus has been investing in India for three decades and, over time, has one of the country’s most established healthcare investment franchises, the note said. The firm has partnered with businesses across pharmaceuticals, medical technology, healthcare services and life sciences, including Metropolis, Laurus Labs, MedPlus, Meril Life Sciences and Appasamy Associates.